Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma
Paul M. Clément(Universitair Ziekenhuis Leuven), Martin J. van den Bent(Erasmus MC Cancer Institute), Nicolas Whenham(Cliniques Universitaires Saint-Luc), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Michael Weller(University Hospital of Zurich), Linda Dirven(Leiden University Medical Center), Jim Looman(AbbVie (United States)), Filip De Vos(University Medical Center Utrecht), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Jan Peter de Geus(AbbVie (United States)), Paul Sanghera(The Edgbaston Hospital), Corneel Coens(European Organisation for Research and Treatment of Cancer), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Madan G. Kundu(AbbVie (United States)), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Olivier Chinot(Aix-Marseille Université), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Vassilis Golfinopoulos(Champalimaud Foundation), Maarten Spruyt(European Organisation for Research and Treatment of Cancer), Annemiek Walenkamp(University Medical Center Groningen)
Cited by 20
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k